Menu
Recruiting NCT05761366

Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor

Phase II Interventional Malignancy

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Al18F-PSMA-BCH PET/CT.
Who it may be relevant to
Registry conditions: Malignancy. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

In this study, Al18F-PSMA-BCH PET/CT will be performed in patients with prostate specific membrane antigen positive tumor, to evaluate the tumour detection efficacy of Al18F-PSMA-BCH PET/CT.

Detailed description

Al18F-PSMA-BCH PET/CT will be performed on patients with suspected or clearly diagnosed PSMA positive-expressing tumors (including prostate cancer, transitional epithelial carcinoma, colon carcinoma, adenoid cystadenocarcinoma, mesothelioma, hepatocellular carcinoma, cholangiocellular carcinoma, multiple myeloma, etc.) , to evaluate the tumour detection efficacy of Al18F-PSMA-BCH PET/CT.

Interventions

  • Drug Al18F-PSMA-BCH PET/CT
    Patients will be intravenously injected with Al18F-PSMA-BCH and undergo PET/CT scan.

Primary outcome measures

  • Diagnostic value [Time frame: through study completion, an average of 1 year]

Eligibility criteria

Inclusion criteria

  • Patients with suspected or clearly diagnosed PSMA positive-expressing tumors, including prostate cancer, transitional epithelial carcinoma, colon carcinoma, adenoid cystadenocarcinoma, mesothelioma, hepatocellular carcinoma, cholangiocellular carcinoma, multiple myeloma, etc.
  • Age is 18 or older; No gender limitation.
  • Signed the informed consent.
  • Willing and able to cooperate with all projects in this study.

Exclusion criteria

  • Patients with serious neurological diseases,or gastrointestinal tract disease, cardiovascular disease, liver disease, kidney disease, blood system disease, endocrine system disease, respiratory system disease, immune deficiency disease, etc
  • Claustrophobia.
  • Pregnant or lactation women.
  • Received experimental drug or device within 1 month.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Diagnostic

Study locations

China · 1 center
  • National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Unio — Beijing

Identifiers

NCT: NCT05761366 · NCC3688

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗